<DOC>
	<DOCNO>NCT02463643</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Z-215 ( 10 mg , 20 mg , 40 mg ) , compare Rabeprazole Sodium 10mg patient erosive esophagitis Grade A D define LA classification grade system .</brief_summary>
	<brief_title>To Evaluate Efficacy Safety Z-215 Erosive Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>In observation period , participant must endoscopically confirm erosive esophagitis Grade A D , define LA classification grade system , target number participant clearly Grade C D 20 % ( 96 participant ) total participant . Outpatient ( include inpatient examination ) Participants previous current history eosinophilic esophagitis , scleroderma , esophageal stenosis , esophageal varix , Barrett 's esophagus ( columnar epithelium metaplasia &gt; =3 cm ) highgrade dysplasia.However , participant Schatzki 's ring ( &gt; =20mm ) allow include . Participants acute upper gastrointestinal bleeding , gastric duodenal ulcer ( mucosal defect white coating &gt; =3mm ) within 28 day prior observation period . Participants disease endoscopy observation period . Participants ZollingerEllison syndrome.Participants suspect gastric acid hypersecretion disorder attributable hyperparathyroidism others . Participants previous history surgery esophagus , stomach duodenum ( exclude removal benign polyp endoscopic polypectomy ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>